Intermittent Liposomal Amphotericin B Primary Prophylaxis
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when
used as a preventer against invasive fungal infection in patients with acute leukaemia who
are undergoing chemotherapy.